The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Camizestrant plus ribociclib in hormone receptor–positive/HER2-negative advanced breast cancer: The phase II CADILLAC trial.
 
Javier Cortes
Stock and Other Ownership Interests - Leuko (I); MAJ3 Capital
Honoraria - AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung; Steamline Therapeutics; Zuellig Pharma
Consulting or Advisory Role - Abbvie; AstraZeneca; Athenex; Bioasis; Biocon; Bioinvent; BioNTech SE; Bliss Biopharmaceutical; Boehringer Ingelheim; Bridgebio; Celgene; Cellestia Biotech; Circle Pharma; Clovis Oncology; Daiichi Sankyo; Delcath Systems; Ellipses Pharma; ERYTECH Pharma; Expres2ion Biotechnologies; GEMoaB; Gilead Sciences; GlaxoSmithKline; Hexagon Bio; HiberCell; Jazz Pharmaceuticals; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Relay Therapeutics; Reveal Genomics; Roche; Seagen; SERVIER; Zymeworks
Research Funding - ARIAD (Inst); Astrazeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A.
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Merck Sharp&Dhome; Novartis; Pfizer; Roche; Steamline Therapeutics
 
Angel Guerrero-Zotano
Consulting or Advisory Role - Exact Sciences; Novartis; Pierre Fabre; Roche
Speakers' Bureau - AstraZeneca; Lilly; Menarini; Novartis
Expert Testimony - AstraZeneca; Lilly; Menarini; Novartis; Pfizer; Pierre Fabre
Travel, Accommodations, Expenses - Gilead Sciences; Menarini; Novartis; Roche
 
Maria Gion
Consulting or Advisory Role - AstraZeneca; Lilly; Pfizer
Speakers' Bureau - AstraZeneca; Gilead Sciences; Novartis; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; Pfizer; Roche
 
Cristina Alba Torres
Honoraria - Lilly; Novartis
 
Luis De La Cruz
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; Incyte; MSD Oncology; Roche (Inst)
Speakers' Bureau - Abbvie
Research Funding - Celgene (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Roche
 
Ana López González
Honoraria - AstraZeneca; Novartis
Consulting or Advisory Role - AstraZeneca; Novartis
Travel, Accommodations, Expenses - Gilead Sciences
 
Jose Ponce-Lorenzo
Honoraria - Agendia; AstraZeneca/Daiichi Sankyo; Gilead Sciences; Lilly; Novartis; Pfizer; Seagen
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Novartis; Pierre Fabré; Roche; Seagen
 
Michael Untch
Honoraria - AstraZeneca; AstraZeneca (Inst); Baxter Middle East; Daiji Sankyo (Inst); Eisai Germany (Inst); Lilly (Inst); Menarini Group (Inst); MSD Oncology (Inst); Myriad Genetics (Inst); Novartis (Inst); Roche Pharma AG (Inst); Sanofi (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); BeOne Germany (Inst); CD Pharma (Inst); ClinSol; Daiichi Sankyo Europe GmbH (Inst); EuroBio Scientific (Inst); Lilly (Inst); Menarini Group (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche Pharma AG (Inst); Sandoz Hexal (Inst); Sanofi Aventis GmbH (Inst)
 
Carmen Mora Gallardo
Other Relationship - MedSIR
 
Michela Verbeni
Other Relationship - MedSIR
 
Mireia Pedragosa
Other Relationship - MedSIR
 
Janat Fazal-Salom
Other Relationship - MedSIR
 
Maryna Todoriuk
Other Relationship - MedSIR
 
José Manuel Pérez García
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Merck Sharp & Dohme; Roche; Seattle Genetics/Astellas
Travel, Accommodations, Expenses - Roche
Other Relationship - MedSIR
 
Antonio Llombart-Cussac
Stock and Other Ownership Interests - Initia-Research; MAJ3 Capital
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Lilly; MSD; Novartis; Pfizer
Research Funding - Agendia; Daiichi Sankyo Europe GmbH; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1. LICENSED
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; Pfizer; Roche; Steamline Therapeutics